Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

RETA Reata Pharmaceuticals

25.280
+2.070+8.92%
Close 09/28 16:00 ET
25.2800.0000.00%
Post Mkt Price 09/28 16:02 ET
High
25.960
Open
23.720
Turnover
18.10M
Low
23.720
Pre Close
23.210
Volume
714.41K
Market Cap
922.63M
P/E(TTM)
Loss
52wk High
114.800
Shares
36.50M
P/E(Static)
Loss
52wk Low
18.470
Float Cap
759.60M
Bid/Ask %
-66.67%
Historical High
257.965
Shs Float
30.05M
Volume Ratio
1.02
Historical Low
11.030
Dividend TTM
--
Div Yield TTM
--
P/B
13.44
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
2.38%
Amplitude
9.65%
Avg Price
25.335
Lot Size
1
Float Cap
759.60M
Bid/Ask %
-66.67%
Historical High
257.965
Shs Float
30.05M
Volume Ratio
1.02
Historical Low
11.030
Dividend TTM
--
P/B
13.44
Dividend LFY
--
Turnover Ratio
2.38%
Amplitude
9.65%
Avg Price
25.335
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.
CEO: Mr. J. Warren Huff
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...